IL10 and neoplasm: In vivo, a significant reduction (~89%) in tumor burden and favorable modulation of inflammation, characterized by a decrease in pro‐inflammatory cytokines (TNF‐α, IFN‐γ, IL‐6, VEGF) and an increase in anti‐inflammatory IL‐10 was observed.